Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$14.70
+0.1%
$14.64
$6.41
$14.77
$940.21M0.84757,360 shs2.39 million shs
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
C$0.04
-12.5%
C$0.05
C$0.03
C$0.09
C$1.33M0.475,091 shs2,000 shs
HEXO Corp. stock logo
HEXO
HEXO
$0.71
+2.5%
$0.87
$0.66
$3.84
$31.24M1.35880,508 shs305,500 shs
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
C$4.73
-0.4%
C$4.29
C$3.34
C$7.12
C$150.98M1.169,501 shs4,512 shs
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
0.00%0.00%0.00%0.00%0.00%
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
0.00%-12.50%-22.22%-22.22%-41.67%
HEXO Corp. stock logo
HEXO
HEXO
0.00%0.00%0.00%0.00%-37.72%
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
0.00%-2.86%+29.08%+16.14%-20.17%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
N/AN/AN/AN/AN/AN/AN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
N/AN/AN/AN/AN/AN/AN/AN/A
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
0.0703 of 5 stars
1.10.01.70.00.60.80.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
N/AN/AN/AN/A
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
N/AN/AN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
N/AN/AN/AN/A
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
2.25
HoldC$4.58-3.28% Downside

Current Analyst Ratings

Latest HLS, HEXO, AMYT, and BMK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/18/2024
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetC$6.50 ➝ C$5.00
3/15/2024
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetC$4.35 ➝ C$4.15
2/22/2024
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetC$5.00 ➝ C$4.35
2/6/2024
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
Clarus Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$222.54M4.22$0.98 per share14.98$5.58 per share2.63
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
C$-74K-17.92C$0.00 per share13.00C($0.01) per share-3.50
HEXO Corp. stock logo
HEXO
HEXO
$146.20M0.21N/AN/A$2.44 per share0.29
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
C$63.07M2.39C$0.31 per share15.22C$3.06 per share1.55

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
$1M-$0.06N/A735.00N/A-8.19%1.70%0.75%N/A
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
-C$1.28M-C$0.02N/AN/AN/A-1,679.48%-324.12%6/4/2024 (Estimated)
HEXO Corp. stock logo
HEXO
HEXO
-$845.90M-$5.21N/AN/AN/A-235.33%-74.04%-32.51%N/A
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
-C$27.53M-C$1.16N/AN/A-43.65%-24.69%-2.87%5/9/2024 (Estimated)

Latest HLS, HEXO, AMYT, and BMK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/14/2024Q4 2023
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
-C$0.13-C$0.18-C$0.05-C$0.13C$21.83 millionC$21.60 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
N/AN/AN/AN/AN/A
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
N/AN/AN/AN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
N/AN/AN/AN/AN/A
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
C$0.204.23%N/AN/A N/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
0.64
1.57
0.94
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
3.84
0.22
0.27
HEXO Corp. stock logo
HEXO
HEXO
0.01
0.41
0.24
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
89.69
1.65
1.01

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
71.31%
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
1.10%
HEXO Corp. stock logo
HEXO
HEXO
7.78%
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
59.62%

Insider Ownership

CompanyInsider Ownership
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
5.66%
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
7.58%
HEXO Corp. stock logo
HEXO
HEXO
4.69%
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
0.49%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Amryt Pharma plc stock logo
AMYT
Amryt Pharma
2,02063.96 million60.34 millionNot Optionable
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
237.88 millionN/ANot Optionable
HEXO Corp. stock logo
HEXO
HEXO
1,27744.00 million41.93 millionOptionable
HLS Therapeutics Inc. stock logo
HLS
HLS Therapeutics
9131.92 millionN/ANot Optionable

HLS, HEXO, AMYT, and BMK Headlines

SourceHeadline
Branching Regulatory Paths and Dead Ends in PsychedelicsBranching Regulatory Paths and Dead Ends in Psychedelics
theregreview.org - April 15 at 1:53 AM
Who Is Cara Mund? Former Miss America Who Supports Abortion Rights Announces Run for US House as Republican in North DakotaWho Is Cara Mund? Former Miss America Who Supports Abortion Rights Announces Run for US House as Republican in North Dakota
ibtimes.sg - April 10 at 12:16 AM
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceHLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 9 at 8:27 AM
Cara Mund running for US House in North Dakota Republican primaryCara Mund running for US House in North Dakota Republican primary
bismarcktribune.com - April 8 at 5:55 PM
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsNew REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
finance.yahoo.com - April 8 at 7:31 AM
Getting to Yes, And…| Elaine Lin Hering – Unlearning SilenceGetting to Yes, And…| Elaine Lin Hering – Unlearning Silence
wgnradio.com - April 2 at 10:55 AM
Earnings Release: Heres Why Analysts Cut Their HLS Therapeutics Inc. (TSE:HLS) Price Target To CA$6.57Earnings Release: Here's Why Analysts Cut Their HLS Therapeutics Inc. (TSE:HLS) Price Target To CA$6.57
finance.yahoo.com - March 17 at 10:03 AM
HLS has price target cut at Raymond JamesHLS has price target cut at Raymond James
cantechletter.com - March 15 at 8:14 PM
HLS Therapeutics Inc. (TSE:HLS) stock most popular amongst retail investors who own 40%, while hedge funds hold 39%HLS Therapeutics Inc. (TSE:HLS) stock most popular amongst retail investors who own 40%, while hedge funds hold 39%
finance.yahoo.com - March 14 at 12:41 PM
HLS Therapeutics Announces Fiscal 2023 Financial ResultsHLS Therapeutics Announces Fiscal 2023 Financial Results
finance.yahoo.com - March 14 at 7:34 AM
HLS Therapeutics earnings: heres what to expectHLS Therapeutics earnings: here's what to expect
markets.businessinsider.com - March 13 at 10:32 AM
Amicus Curiae Returning to CampusAmicus Curiae Returning to Campus
marshallparthenon.com - February 21 at 1:11 PM
Several Insiders Invested In HLS Therapeutics Flagging Positive NewsSeveral Insiders Invested In HLS Therapeutics Flagging Positive News
finance.yahoo.com - February 21 at 1:11 PM
Stocks in play: HLS Therapeutics Inc.Stocks in play: HLS Therapeutics Inc.
ca.finance.yahoo.com - February 6 at 1:07 PM
HLS Announces that Vascepa® is now reimbursed by British Columbias Provincial Drug PlanHLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan
finance.yahoo.com - February 6 at 7:35 AM
Jennifer J. Raab named President and CEO of The New York Stem Cell FoundationJennifer J. Raab named President and CEO of The New York Stem Cell Foundation
eurekalert.org - January 31 at 10:48 PM
Pharma breakthroughs: 10 novel drug approvals that made headlines in 2023Pharma breakthroughs: 10 novel drug approvals that made headlines in 2023
msn.com - December 20 at 11:16 AM
HLS Therapeutics CFO Tim Hendrickson to Step DownHLS Therapeutics CFO Tim Hendrickson to Step Down
marketwatch.com - December 18 at 7:58 AM
HLS Therapeutics appoints John Hanna as interim CFOHLS Therapeutics appoints John Hanna as interim CFO
msn.com - December 18 at 7:58 AM
HLS Therapeutics Announces CFO DepartureHLS Therapeutics Announces CFO Departure
finance.yahoo.com - December 18 at 7:58 AM
2 Top Pharmaceutical Stocks to Buy on the TSX Today2 Top Pharmaceutical Stocks to Buy on the TSX Today
msn.com - December 11 at 7:41 PM
Cerebral venous thrombosis should be considered in a postpartum patient with headache and seizureCerebral venous thrombosis should be considered in a postpartum patient with headache and seizure
cmaj.ca - December 11 at 9:41 AM
Some HLS Therapeutics Inc. (TSE:HLS) Analysts Just Made A Major Cut To Next Years EstimatesSome HLS Therapeutics Inc. (TSE:HLS) Analysts Just Made A Major Cut To Next Year's Estimates
finance.yahoo.com - November 15 at 7:05 AM
New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at BaselineNew REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
finance.yahoo.com - November 14 at 5:47 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Amryt Pharma logo

Amryt Pharma

NASDAQ:AMYT
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.
MacDonald Mines Exploration logo

MacDonald Mines Exploration

CVE:BMK
MacDonald Mines Exploration Ltd. engages in the acquisition, exploration, and development of mineral properties in Canada. The company explores for gold, silver, copper, cobalt, and nickel deposits. It owns 100% interest in the Scadding-Powerline-Jovan property that covers an area of 19,710 hectares located to the east of Sudbury in Northern Ontario. The company was formerly known as MacDonald Mines Limited. MacDonald Mines Exploration Ltd. was incorporated in 1936 and is based in Toronto, Canada.
HEXO logo

HEXO

NYSE:HEXO
HEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.
HLS Therapeutics logo

HLS Therapeutics

TSE:HLS
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.